to Alex. for Dr. we'll Good including you, clinical business analysis. investigator by AACR monotherapy you findings Rezvani joining thank MD other Center, developments at our us patients XXXX. will update Thank Cancer Today with Katy on recent we fourth will review pre-complex NK then of our day, treating AFMXX from at discuss And company, briefly the for quarter and key trial of quarter presented programs call the a fourth Cord call And development. Yes. Anderson interim in futility AFMXX on is to our at the which currently and I progress over and hand the Angus the updates cells. everyone, update our the financial an results. AFMXX provide clinical combination Blood-derived the sponsored
by the of for Affimed year. highlighting We rest call back key and the some milestones week [ph] to of will conclude our this
cancer. clinical share leveraging the are in been our We across undergone to you with making and data part we're Affimed's and XXXX immune on an excited fight to pipeline, system a has innate evolution very in our progress incredible XXXX. the pioneer programs groundbreaking of early demonstrate which
our a part the and technology patients platform, families, in meaningful result engagers good developing for as can that increasing doctors of a the spent for us decade technology, well. them the the our ROCK their rewarding have who evidenced innate We and last in benefits our being patients, for experience clinic; we're and cell very treat
what and they our is killer first-line to including to innate established of years cancer disease. believe naturally the they're we the by protect macrophages, cells and to defense, intended natural Affimed can from molecules we position Over a engaging to what do immunity, for best-in-class have cells develop where guide unique do us our these
innate all our have results to these and work a the now of our of we are see conducted We identify to we lot to support strategy believe chance development of the beginning of engagers have indications cell that believe efforts. best success. preclinical We where
are As vis-à-vis differentiated platforms with our we've helping competing fight approaches and shared you to patients in engagers innate we cancer. believe past, strongly the that cell
kill cell on which to Our as -- all of molecules been via retention CDXXA They binding level which cytotoxicity has cell natural to to cell are and to reduces affinity, with days. have and independent show bind shown cells on the macrophages for effective cells over engagers able killing binding of plasma Innate and cells which been the superior persist several HEG innate are we phagocytosis. acronyms ADCP leading engagers and ADCC shown know natural an expression. over unique tumor on and killer persist CDXXA epitope high to antigen tumor with killer competition
matter Cord they In cells addition, cell of the freezing, is high or design is that autologous; all thawing our case free and targeting. killing showed is coming with the tumor in washing. affinity complex effector how very improved Blood-derived innate you no fully platforms engagers need which need after maintained and advantage important unique that of IPSCs cell these A
enabling killer of strong believe and level, has locate this cell technology we engagers to expression innate that advantage. cells natural where a is target Our independent the our tumor
NK believe whatever is to with. look way our process you at different target work targeting If the the technology tumor cells your we approaches, best
demonstrate and with at cell news engagers. system and of monotherapy from can that last technology innate several analysis validate our both, have combination indications immune pembrolizumab, of where saying systems AFMXX of leverages on cells our to interim provides engagers chance the of NK able encouraging by combining with focuses science cells, highly believe with the aims The innate about in been involvement, or help with our the strategy specific data the outcome T-cell now for I been innate development immune on analysis monotherapy and which peripheral our produce adaptive behind for the month, patient's and our study futility exciting the MD NK these reported indications anti-PDX at Furthermore, review validation high innate of we AFMXX trial; cell AFMXX the as suffer and from inhibitors. last about dysfunctional science we advantages announcement what of the recent Over interim findings combination positive with three-pronged briefly presented positive we data Last innate on activation the the we monotherapy the few the to reported we AFMXX and lymphoma. a weeks. AFMXX clinical cell months, Anderson that in combination have from is checkpoint results. in PDLX would patients the like
CDXX cohort comparability at achieved with includes cells threshold, tumor reminder, expressed XX% cohort defined to from least A. tumors As which had cohort patients sufficient CDXX than up B a CDXX A demonstrates in the to interim of whose X% less predefined as that futility the representing XX% showed that expression lower positivity patients analysis and for
complete and noted we saw high low we that both, responses partial and positive lymphoma CDXX Importantly, expressing in T-cell peripheral patients.
this platform drug fronts. result, the have could study one immune positivity. a after system. undergoing And into We deliver the accelerating with by drug has PTCL continue for patients cohorts the or on CDXX efforts AFMXX power innate set our was the with exhausted to patients multiple monotherapy therapies the leveraging of a two now combining have with to the candidate potential The encouraging experimental discovery that many all will interim including in-house standards of As analysis outcome who benefit options [ph], ROCK therapy. our
lymphomas Center Core be symposium and as sponsored major from to candidates Dr. cohort study, Rezvani patients AACR two one diseases, believe tumors, AFMXX. addressing mentioned, natural cells kilogram, allows of reported investigator AFMXX, well to data the tumor and with at first broad positive treated and pre-complex and of the Meeting, reduction In were As partial a a -- our the per high that Blood-derived this range response. [indiscernible]. EGFR Cancer killer pre-complex a Anderson cells significant all CDXX disease in that with the drug at which first cells the Earlier of NK platform of MD Annual we we patients expressing the with of XX complete lowest and engager experienced responses in three have with other X we presented that wide of unmet fight dose developed, potential innate solid as the best-in-class approach validated needs trial solid week, to
using for therapy. XXX% objective you response what The we're this first now also NK in X kilogram was XX cohort opportunities we Dr. the Rezvani she observed to are single yesterday response to with per cycle believes have patient a with the rate after of complete X; an In total, rate cells discussed pre-complex dose assessed treatment. date. a of
affinity killer validating binding our from meaningful patients. Importantly, the natural delivering we molecules benefits study like [ph] benefits the CAR high results as NK cell of to innate approach see far with the so of to cells engager
leverage approaches provide for differentiating is Our plan transfer, to that our adaptive molecule the customize to now develop unique continue and features cell to combination options NK with in of and recruiting a cells of in The the kilogram. X tumors treating the treating per currently to in hematology and XX variety is cohort the and study patients future. second solid with NK
to with patients and Rezvani on Anderson success will the update her provide stories We expect MD updates throughout year. and on colleagues study continue in us Dr. the the
innate cells cell first XX%. immunotherapies, about reduction data trial manageable that The approach us knowledge publication to and could well innate the was molecule leveraging Society Xb NK for with upon experience inhibitor last validation and AFMXX disease proof-of-concept year Affimed, American are we inhibitor of growing as provides current objective cell This treatment, of and the the was provides XX% with significant response combination of confirmation response side-effects. critical an objective shows step this engager activation Furthermore, anti-PDX activity. Finally, development checkpoint high demonstrated a therapy. time clinical that with study rate as one in applying an The highest complete be in of PDX are published AFMXX phase harnessing the innate we state indicated monotherapy our administered other The improve across combination believe rate the of rate from and of data of clinical study safely response at with and evidence late in it ability it that from protein Merck now final the of in rate as checkpoint Hematology. we immunity forward of with program. very in of KEYTRUDA complete and Journal trials the another response our engager The combination our the our our
with develop clinical Now, we adaptive that cells. notably any shows other with low to from substantial in meaningful even efficacy innate AFMXX drive data AFMXX program monotherapy natural at have with support inhibitors can demonstrating synergy generate less by our we cell the our of working development NK doses generated strategy checkpoint responses cells from the to engagers AFMXX. killer way candidate, is and pipeline The AFMXX informing data concept
too Here we very making progress. are good
milligram trial dose that X In dose which have solid escalation specific At this portion on is phase not tolerated escalation comers AFMXX. pharmacodynamically now no to patients of dose dosing patients evaluate plan dose we cell have monotherapy of treating any study phase of is any the into XXX trial. the refractory this the on of and stage call. use clinical will active the recruiting specific recommended to we our at expansion have the safety us AFMXX completed EGFR milligram efficacy The of phase a cohort announced expansion yet yet which a next is to yet trial the to continue dose escalation dose in X at enroll X. we We various involvement, evaluate X/Xa the enrolling ongoing establish type. cohort cohorts, portion enriched escalation is of the phase patients dose we reached progression dose in the is innate enable AFMXX dose information with and at and a Our we're the are to earnings have and can we at The and that tolerability expressing and in this indication further for XXX all morning objective to nor of maximum that dose, of with currently any relapsed tumor should We'll was we patients and the indicate our updates escalate. don't tumors. we
trial We half. start the phase in of dose expansion the expect to second the
of by study as continued NK have cleared with [indiscernible] AFMXX make cell also We AFMXX combination the initiation announced progress product recently good was INDs the the FDA. the to for that a combination cells. adoptive with of NKXX autologous of We NK with
potential EGFR data demonstrating demonstrate model establishing well or proof-of-concept And tumor AACR diminished year's combination presence unaffected to greatly for study NK that In leads combination cytotoxic kill IgG. very AFMXX's our for ADCP response, was tumor clinical completing a of believe to that X/Xa clinical to Conference. this reasons mutations in were EGFR KRAS very by of the to induces for given we tightly against combination. The activation regression as combination by in to with irrespective AFMXX. presence poster, cells In cells XXXX. tumor adoptive the paper initiate drug competing was -- mouse xenograft the killer potential about candidate. initial MD the dose-dependent expressing polyclonal differentiated with expect the We indeed of Anderson natural that cells poster IgG. as of adding at important a this to the macrophages, a supported AFMXX it's shown data We're to able in phase on data AFMXX stark further promising ability from further This second positive cytotoxic by to bind this potential half highly showed prominent poster [indiscernible] the was this further cells, strong of pre-clinical that in a finding contrast, AFMXX excited added the
combination fight Thirdly, combination and in anti-PDLX we've of checkpoint atezo, leverage innate plan AFMXX believe immune our could the with an atezo investigate inhibitors. adaptive with to cancer. also AFMXX in the accelerated systems against We the Roche's
phase the in evaluating combination X/Xa the dose of half expect study the to XXXX. the second patient in first We
this molecule our engager third and continues including information, obviously studies, to IND later AFMXX Now, data. year release IND enabling plan to the owned innate advance details more cell wholly this enabling and pre-clinical through about then we about target, the program
collaborations, Roivant programs. closely our continued their we they Genentech move and as at work to also Looking have in with
the partnerships study. And very is trial the XXXX [ph]. -- we've our BCMA which our targeting these presenting of happy a are engager CDXXA how XXXX in phase details Recall, former announced we clinical with We the entered partnership dependent are developing. -- two that August X are last cell innate as past, on AFMXX, said
pre-clinical is we are in the move it… AFMXX with As Roivant and concerned, Difficulty] far as you partnership collaborating case, just them for missed work forward, [Technical to
